These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 18457470)

  • 1. Agomelatine: AGO 178, AGO178, S 20098.
    Drugs R D; 2008; 9(3):177-83. PubMed ID: 18457470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agomelatine for the treatment of major depressive disorder.
    Carney RM; Shelton RC
    Expert Opin Pharmacother; 2011 Oct; 12(15):2411-9. PubMed ID: 21916789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.
    Bourin M; Prica C
    Curr Pharm Des; 2009; 15(14):1675-82. PubMed ID: 19442180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agomelatine targets a range of major depressive disorder symptoms.
    Dubocovich ML
    Curr Opin Investig Drugs; 2006 Jul; 7(7):670-80. PubMed ID: 16869122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agomelatine, a melatonin agonist with antidepressant properties.
    Dubovsky SL; Warren C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1533-40. PubMed ID: 19758108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.
    Kasper S; Hamon M
    World J Biol Psychiatry; 2009; 10(2):117-26. PubMed ID: 19255935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agomelatine: new drug. Adverse effects and no proven efficacy.
    Prescrire Int; 2009 Dec; 18(104):241-5. PubMed ID: 20020562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine: efficacy at each phase of antidepressant treatment.
    Kennedy SH
    CNS Drugs; 2009; 23 Suppl 2():41-7. PubMed ID: 19708725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial.
    Goodwin GM; Emsley R; Rembry S; Rouillon F;
    J Clin Psychiatry; 2009 Aug; 70(8):1128-37. PubMed ID: 19689920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Agomelatine: a novel pharmacological approach to treating depression.
    Owen RT
    Drugs Today (Barc); 2009 Aug; 45(8):599-608. PubMed ID: 19927226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The mechanism, efficacy, and tolerability profile of agomelatine.
    MacIsaac SE; Carvalho AF; Cha DS; Mansur RB; McIntyre RS
    Expert Opin Pharmacother; 2014 Feb; 15(2):259-74. PubMed ID: 24328686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine.
    De Berardis D; Di Iorio G; Acciavatti T; Conti C; Serroni N; Olivieri L; Cavuto M; Martinotti G; Janiri L; Moschetta FS; Conti P; Di Giannantonio M
    CNS Neurol Disord Drug Targets; 2011 Feb; 10(1):119-32. PubMed ID: 20874703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical studies on the efficacy of agomelatine on depressive symptoms.
    Goodwin GM
    CNS Drugs; 2009; 23 Suppl 2():35-9. PubMed ID: 19708724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of agomelatine in children and adolescents with major depressive disorder receiving psychosocial counselling: a double-blind, randomised, controlled, phase 3 trial in nine countries.
    Arango C; Buitelaar JK; Fegert JM; Olivier V; Pénélaud PF; Marx U; Chimits D; Falissard B;
    Lancet Psychiatry; 2022 Feb; 9(2):113-124. PubMed ID: 34919834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agomelatine: a preliminary review of a new antidepressant.
    Zupancic M; Guilleminault C
    CNS Drugs; 2006; 20(12):981-92. PubMed ID: 17140278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A benefit-risk assessment of agomelatine in the treatment of major depression.
    Howland RH
    Drug Saf; 2011 Sep; 34(9):709-31. PubMed ID: 21830835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness.
    Kennedy SH; Rizvi SJ
    CNS Drugs; 2010 Jun; 24(6):479-99. PubMed ID: 20192279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine.
    Lemoine P; Guilleminault C; Alvarez E
    J Clin Psychiatry; 2007 Nov; 68(11):1723-32. PubMed ID: 18052566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.